Compound as potassium channel modulator and their preparation and use

A technology of compounds and uses, applied in the field of biomedicine, can solve problems such as poor selectivity and adverse effects

Active Publication Date: 2021-11-26
SHANGHAI ZHIMENG BIOPHARMA CO LTD
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Potential adverse effects of RTG due to broad action on all Kv7

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound as potassium channel modulator and their preparation and use
  • Compound as potassium channel modulator and their preparation and use
  • Compound as potassium channel modulator and their preparation and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] The preparation of embodiment 1 compound A

[0061]

[0062] Step 1, compound 2

[0063] Compound 1 (2.0 g, 10.0 mmol, 1.0 eq) was dissolved in ethyl acetate (100 mL), and 2-(1-methylcyclopropyl)acetic acid (cas:71199-15-0, 1.26 g, 11.0 mmol , 1.1 eq), pyridine (7.9 g, 99.96mmol, 10.0 eq) and T 3 P (50%, 31.8 g, 49.97 mmol, 5.0 eq), heated to 50°C and stirred for 16 hours. After cooling to 25 ºC, dilute with water and extract with ethyl acetate (3 x 100 mL). The combined organic phases were washed with saturated sodium chloride solution and dried over anhydrous sodium sulfate, and the concentrated residue was purified by silica gel column chromatography (petroleum ether / ethyl acetate=10 / 1) to obtain compound 2 (2.5 g, 84 %) as a white solid.

[0064] LCMS: [M+H] + = 296.0

[0065] Step 2, Compound A

[0066] Compound 3 (224mg, 0.61mmol, 1.2eq) was dissolved in toluene (5 mL), followed by adding compound 2 (150mg, 0.51mmol, 1.0 eq), potassium tert-butoxide (172...

Embodiment 2

[0069] Example 2 Potassium channel opener agonist rate test (FDSS / μCELL detection)

[0070] 1. Experimental method:

[0071] 1.1 Experimental process

[0072] Cell preparation: CHO-KCNQ2 cells were cultured at 175 cm 2 In the culture flask, when the cell density grows to 60-80%, remove the culture medium, wash with 7 mL PBS (Phosphate Buffered Saline, phosphate buffer saline), and then add 3 mL 0.25% Trypsin for digestion. After the digestion is complete, add 7 mL of culture medium (90% DMEM / F12 + 10% FBS + 500 μg / mL G418) to neutralize, centrifuge at 800 rpm for 3 minutes, suck off the supernatant, and then add 5 mL of culture medium to resuspend the cells. count.

[0073] Cell plating: Adjust the density to 3x10 according to the cell count results 4 per well, after standing at room temperature for 30 minutes, place in 37°C CO 2 Incubate overnight in an incubator for 16-18 hours to reach a cell density of approximately 80%.

[0074] Fluorescent dye incubation: Discard t...

Embodiment 3

[0101] The research of embodiment 3 compound through blood-brain barrier ability

[0102] 1) Research purpose: In order to obtain the situation of the tested compound passing through the blood-brain barrier

[0103] 2) Experimental content

[0104] Take 9 healthy male ICR mice (body weight range: 18-22 grams), divide them into 3 groups, 3 mice / group, orally administer the compound to be tested after fasting overnight, and undergo cardiac puncture at time points 1h, 2h and 4h Blood collection, collect at least 0.5 mL whole blood to EDTA-K 2 Centrifuge the anticoagulant tube within half an hour to collect plasma (6000 rpm, 8 minutes, 4°C), and freeze it at -20°C for later use. At the same time, the brain tissue was collected, rinsed with normal saline, blotted dry with absorbent paper, weighed, and frozen at -20°C for later use.

[0105] Experimental results: According to the obtained blood drug concentration data, the pharmacokinetic parameters after administration were calc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a compound as a potassium channel modulator and preparation and application thereof. Specifically, the compound provided by the invention has a structure as shown in a formula A. The invention also discloses a preparation method of the compound and application of the compound as a potassium channel regulator. Formula A.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to compounds as potassium channel modulators and their preparation and application. Background technique [0002] Kv7 potassium channel is a kind of voltage-dependent potassium ion channel, which has the characteristics of low threshold activation, slow activation and non-inactivation. The Kv7 potassium channel has five family members (Kv7.1-Kv7.5), and all Kv7 potassium channel members have a similar topology, that is, a functional channel consists of four subunits, each subunit contains six Transmembrane segment (S1-S6). Among them, S4 is the voltage sensing region, which plays an important role in sensing membrane potential changes and controlling conformational changes; SS-S6 is the main component of the channel pore region, and is the main combination and action region of potassium channel openers. The KV7.1 potassium channel is a non-neuronal pathway distributed in peripheral tiss...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07D217/04A61P25/08A61P29/00A61P25/00A61P25/04A61P25/06A61P25/24A61P9/10A61P25/28A61K31/472
CPCC07D217/04A61P25/08A61P29/00A61P25/00A61P25/04A61P25/06A61P25/24A61P9/10A61P25/28
Inventor 梁波刘刚陈焕明
Owner SHANGHAI ZHIMENG BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products